adefovir dipivoxil + indinavir + zidovudine

Adefovir dipivoxil + indinavir + zidovudine is a combination of three antiretroviral drugs, each with distinct antiviral mechanisms, primarily investigated as potential therapy for HIV infection. **Adefovir dipivoxil** is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate, which is phosphorylated to inhibit viral DNA polymerase and cause chain termination, mainly used for hepatitis B but active against a range of viruses including HIV. **Indinavir** is a protease inhibitor that prevents cleavage of viral polyprotein precursors required for HIV maturation. **Zidovudine** (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by causing DNA chain termination. This triple combination has been studied in highly treatment-experienced HIV populations, with other NRTIs (e.g., lamivudine) sometimes substituted in clinical trials. No unique brand or fixed-dose formulation is known for this specific three-drug combo; all agents are individually approved antiretrovirals.